Overexpression of shugoshin1 predicts a poor prognosis for prostate cancer and promotes metastasis by affecting epithelial–mesenchymal transition
Authors Mu J, Fan L, Liu D, Zhu D
Received 17 October 2018
Accepted for publication 17 January 2019
Published 8 February 2019 Volume 2019:12 Pages 1111—1118
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Amy Norman
Peer reviewer comments 2
Editor who approved publication: Dr William Cho
Jiagui Mu,1 Li Fan,1 Duo Liu,1 Dongsheng Zhu2
1Department of Urology, The Second People’s Hospital of Lianyungang, Lianyungang Tumor Hospital, Lianyungang Hospital Affiliated to Bengbu Medical University, Haizhou District, Lianyungang 22200, China; 2Department of Graduate School Urology, Tianjin Medical University, Heping District, Tianjin 300000, China
Objective: The aim of the study was to investigate the role of shugoshinl (SGO1) in human prostate cancer (PCa).
Materials and methods: Quantitative real-time PCR (qRT-PCR) was used to determine the expression of SGO1 in PCa tissues and cell lines. The correlation between SGO1 expression and clinicopathological characteristics of PCa patients was analyzed using Kaplan–Meier analysis. SGO1 siRNA was successfully constructed and transfected into PCa cell lines (LNCaP and PC3). The knockdown efficacy was assessed by qRT-PCR. MTT assay and Transwell assay were conducted to observe the effect of SGO1 on the proliferation and invasion of PCa cell lines.
Results: SGO1-expression levels were found to be higher in the PCa tissues and cell lines. Correlation was identified between the expression of SGO1 and preoperative prostate-specific antigen (P=0.017), lymph-node metastasis (P=0.044), and Gleason score (P=0.041). Patients with higher SGO1 expression displayed more advanced clinicopathological characteristics in addition to a shorter biochemical recurrence-free survival time. Additionally, SGO1 knockdown resulted in the inhibition of PCa cell proliferation, migration, and invasion.
Conclusion: Taken together, the findings of the current study present evidence suggesting that SGO1 could inhibit the growth and invasion of PCa cells, highlighting its potential as a novel therapeutic target for the treatment of PCa.
Keywords: shugoshinl, prostate cancer, RNAi
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]